Board approves signing agreement to acquire majority stake in Bion Therapeutics via wholly owned subsidiary
Board of Sai Parenterals Ltd, at its meeting on 16 November 2026, approved signing an agreement, through wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Bion Therapeutics (India) Private Limited.
By ScoutQuest · · 2 min read
- Target Turnover
- Rs. 28.22 Cr for the half-year ended 30 September 2026
- Expected Completion
- on or before 30 November 2026
- Deal Funding
- IPO proceeds earmarked for General Corporate Purposes and debt
What the board approved
- A board meeting held on 16 November 2026 considered and approved signing an agreement, through wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Bion Therapeutics (India) Private Limited.
- The transaction is an all-cash deal. The cost of acquisition is to be based on the valuation of Bion as determined by an independent valuer.
- Bion will become a step-down subsidiary of Sai Parenterals on completion of the deal.
- The indicative time period for completion is on or before 30 November 2026.
- The update states that governmental or regulatory approvals are not required for the acquisition.
Who is being acquired
The target, Bion Therapeutics (India) Private Limited, was incorporated on 5 September 2005 to undertake testing, analysis and examination of pharmaceuticals, medicines, drugs and other materials. The update describes it as a Hyderabad-based branded formulations prescription business operating in the pharma sector.
Size of the target
- Turnover of Rs. 28.22 Cr for the half-year ended 30 September 2026.
- Total income of 47.14 crore in 2024-25 and 47.29 crore in 2025-26.
- Total income of 28.75 crore for the half-year ended 30 September 2026.
How it is being funded
The board also approved providing the necessary funding support to SP Analytics Private Limited for completing the proposed acquisition, through utilisation of the proceeds earmarked for General Corporate Purposes (GCP) from the company's IPO proceeds and debt, subject to applicable laws and requisite approvals.
Related party angle
The update states the transaction will be evaluated in accordance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to related party transaction requirements, and that the interest, if any, of the Promoter(s)/Promoter Group in the target entity or the selling shareholders shall be disclosed as applicable. The acquisition is intended to be undertaken on an arm's-length basis, subject to appropriate assessment and valuation, wherever applicable.
Points a retail investor can track
- Whether completion lands within the indicated window of on or before 30 November 2026.
- The consideration, which the update ties to the independent valuer's valuation of Bion.
- The stake level, described in the update as a majority stake and/or controlling interest.
- The use of IPO proceeds earmarked for General Corporate Purposes towards this acquisition, alongside debt.
Also from Sai Parenterals
Q2 FY27 call: both IPO-funded acquisitions complete, Saicriti injectable plant targeted for July 2027
7 Nov 2026
Sai Parenterals makes available audio recording of Q2 FY27 post-earnings conference call held 2nd November, 2026
2 Nov 2026
Sai Parenterals investor presentation: Q2 FY27 revenue jumps on Noumed consolidation as Rs. 571 crore capex builds
1 Nov 2026
More numbers
- Bion Therapeutics turnover, half-year ended 30 September 2026Rupees 28.22 Cr
- Bion Therapeutics total income, 2024-2547.14
- Bion Therapeutics total income, 2025-2647.29
- Bion Therapeutics total income, half-year ended 30 September 202628.75
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.